Brainstorm Cell Therapeutics Raises $2 Million for Clinical Advancements

On February 26, 2026, Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a prominent developer of adult stem cell therapies for neurodegenerative diseases, announced a successful second strategic private placement, securing an additional $1 million. This new financing brings the total capital raised in February 2026 to $2 million, reinforcing the company’s position as it seeks to advance its regulatory and clinical objectives.

Details of the Strategic Placement

The second placement features market-aligned pricing, with common stock priced at $0.60 per share, closely matching recent market performance, which saw shares closing at $0.615 on the finalization day. This strategic move includes high-conviction warrants, offering 120% warrant coverage with an exercise price of $1.00 per share. This strike price is viewed as a significant valuation target by institutional partners, indicating their expectation for the company’s appreciation as it meets upcoming milestones.

The investment is structured to provide liquidity through staged installments, with the potential for up to eight payments. This arrangement aims to deliver consistent cash flows, supporting near-term operational objectives and preparatory work for the planned Phase 3b trial of its leading therapy, NurOwn.

Chaim Lebovits, President and CEO of Brainstorm, expressed confidence in the funding, stating, “We believe that securing a cumulative $2 million in a single week establishes a floor for our valuation and reflects the market’s growing confidence in our trajectory.” He emphasized that the recent capital influx, alongside disciplined management of legacy liabilities, significantly extends the company’s operational runway.

Funding Utilization and Clinical Development

The proceeds from this funding will be allocated for working capital and general corporate purposes, particularly to support ongoing regulatory and clinical development initiatives. The critical focus remains on advancing the NurOwn® technology platform, which employs autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to target neurodegenerative disease pathways effectively.

NurOwn® is Brainstorm’s flagship investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A completed Phase 3 trial in ALS (NCT03280056) has paved the way for a second Phase 3b trial, set to launch under a Special Protocol Assessment agreement with the FDA.

The clinical program for NurOwn has yielded significant insights into ALS disease biology, including pharmacogenomic responses associated with the UNC13A genotype and biomarker data collected across various longitudinal time points. Brainstorm has actively shared its findings in several peer-reviewed journals, contributing to the broader understanding of ALS.

In addition to ALS, Brainstorm has initiated a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. The company is also advancing a proprietary, allogeneic exosome-based platform aimed at delivering therapeutic proteins and nucleic acids, further expanding its innovative capabilities in regenerative medicine.

With the recent Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, Brainstorm is solidifying its intellectual property portfolio in this emerging field.

For further information on Brainstorm Cell Therapeutics and its initiatives, visit www.brainstorm-cell.com.

This announcement contains forward-looking statements subject to risks and uncertainties, including those related to regulatory approvals and the clinical development of NurOwn. Readers are encouraged to consider these factors carefully when evaluating the company’s future prospects.